Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells

Author(s): Xiaohui Wang, Ying Yu, Lingna Zang, Peng Zhang, Jinfeng Ma*, Dong Chen*

Journal Name: Current Pharmaceutical Biotechnology

Volume 21 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Objective: The aim of the study was to investigate the expression of sCLU in relation to the clinicopathological features and prognosis of patients with untreated High-Grade Osteosarcoma (HGOS) and to evaluate sCLU as a target for osteosarcoma (OS) therapies.

Methods: The expression of sCLU in 98 patients of HGOS enrolled from April 2005 to March 2015 at the affiliated hospital of Qingdao University was evaluated by immunohistochemistry. The sCLU expression, clinical data and survival were compared. siRNA-mediated sCLU gene silencing on cell apoptosis, viability, invasion and chemosensitivity to doxorubicin in U2OS cells in vitro was evaluated.

Results: sCLU expression was found in 59 (60%) of the 98 patients. A positive correlation was observed between sCLU expression and metastatic disease (P = 0.036) and a negative correlation between sCLU expression and response to chemotherapy (P = 0.002). Targeting sCLU expression in U2OS cells induced significant reduction in cellular growth and higher rates of spontaneous endogenous apoptosis. In addition, targeting sCLU expression inhibited the invasion of U2OS cells. Furthermore, targeting sCLU expression significantly sensitized to chemotherapeutic drug, doxorubicin.

Conclusion: The overexpression of sCLU was significantly correlated with metastasis and chemosensitivity in patients with HGOS. sCLU may be a promising therapeutic or chemopreventive target for human OS treatment.

Keywords: Osteosarcoma, secretory clusterin (sCLU), chemotherapy, invasion, apoptosis, HGOS.

[1]
Longhi, A.; Errani, C.; De Paolis, M.; Mercuri, M.; Bacci, G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev., 2006, 32(6), 423-436.
[http://dx.doi.org/10.1016/j.ctrv.2006.05.005] [PMID: 16860938]
[2]
Daw, N.C.; Chou, A.J.; Jaffe, N.; Rao, B.N.; Billups, C.A.; Rodriguez-Galindo, C.; Meyers, P.A.; Huh, W.W. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review. Br. J. Cancer, 2015, 112(2), 278-282.
[http://dx.doi.org/10.1038/bjc.2014.585] [PMID: 25422914]
[3]
Luetke, A.; Meyers, P.A.; Lewis, I.; Juergens, H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat. Rev., 2014, 40(4), 523-532.
[http://dx.doi.org/10.1016/j.ctrv.2013.11.006] [PMID: 24345772]
[4]
Ogawa, Y.; Takahashi, T.; Kobayashi, T.; Kariya, S.; Nishioka, A.; Mizobuchi, H.; Noguchi, M.; Hamasato, S.; Tani, T.; Seguchi, H.; Yoshida, S.; Sonobe, H. Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against irradiation. Int. J. Mol. Med., 2003, 12(4), 453-458.
[http://dx.doi.org/10.3892/ijmm.12.4.453] [PMID: 12964018]
[5]
Fuchs, B.; Pritchard, D.J. Etiology of osteosarcoma. Clin. Orthop. Relat. Res., 2002, (397), 40-52.
[http://dx.doi.org/10.1097/00003086-200204000-00007] [PMID: 11953594]
[6]
Zoubeidi, A.; Chi, K.; Gleave, M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin. Cancer Res., 2010, 16(4), 1088-1093.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2917] [PMID: 20145158]
[7]
Panico, F.; Rizzi, F.; Fabbri, L.M.; Bettuzzi, S.; Luppi, F. Clusterin (CLU) and lung cancer. Adv. Cancer Res., 2009, 105, 63-76.
[http://dx.doi.org/10.1016/S0065-230X(09)05004-0] [PMID: 19879423]
[8]
He, L.R.; Liu, M.Z.; Li, B.K.; Rao, H.L.; Liao, Y.J.; Zhang, L.J.; Guan, X.Y.; Zeng, Y.X.; Xie, D. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci., 2009, 100(12), 2354-2360.
[http://dx.doi.org/10.1111/j.1349-7006.2009.01349.x] [PMID: 19793084]
[9]
Danik, M.; Chabot, J.G.; Mercier, C.; Benabid, A.L.; Chauvin, C.; Quirion, R.; Suh, M. Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc. Natl. Acad. Sci. USA, 1991, 88(19), 8577-8581.
[http://dx.doi.org/10.1073/pnas.88.19.8577] [PMID: 1924317]
[10]
Lau, S.H.; Sham, J.S.; Xie, D.; Tzang, C.H.; Tang, D.; Ma, N.; Hu, L.; Wang, Y.; Wen, J.M.; Xiao, G.; Zhang, W.M.; Lau, G.K.; Yang, M.; Guan, X.Y. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene, 2006, 25(8), 1242-1250.
[http://dx.doi.org/10.1038/sj.onc.1209141] [PMID: 16247463]
[11]
Muhammad, L.A.; Saad, F. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target. Expert Rev. Anticancer Ther., 2015, 15(9), 1049-1061.
[http://dx.doi.org/10.1586/14737140.2015.1064769] [PMID: 26313417]
[12]
Miyake, H.; Chi, K.N.; Gleave, M.E. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res., 2000, 6(5), 1655-1663.
[PMID: 10815883]
[13]
Criswell, T.; Beman, M.; Araki, S.; Leskov, K.; Cataldo, E.; Mayo, L.D.; Boothman, D.A. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J. Biol. Chem., 2005, 280(14), 14212-14221.
[http://dx.doi.org/10.1074/jbc.M412569200] [PMID: 15689620]
[14]
Viard, I.; Wehrli, P.; Jornot, L.; Bullani, R.; Vechietti, J.L.; Schifferli, J.A.; Tschopp, J.; French, L.E. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J. Invest. Dermatol., 1999, 112(3), 290-296.
[http://dx.doi.org/10.1046/j.1523-1747.1999.00531.x] [PMID: 10084304]
[15]
Sallman, D.A.; Chen, X.; Zhong, B.; Gilvary, D.L.; Zhou, J.; Wei, S.; Djeu, J.Y. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol. Cancer Ther., 2007, 6(11), 2938-2947.
[http://dx.doi.org/10.1158/1535-7163.MCT-07-0345] [PMID: 18025278]
[16]
Rosen, G.; Caparros, B.; Huvos, A.G.; Kosloff, C.; Nirenberg, A.; Cacavio, A.; Marcove, R.C.; Lane, J.M.; Mehta, B.; Urban, C. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer, 1982, 49(6), 1221-1230.
[http://dx.doi.org/10.1002/1097-0142(19820315)49:6<1221:AID-CNCR2820490625>3.0.CO;2-E] [PMID: 6174200]
[17]
Chen, Q.; Wang, Z.; Zhang, K.; Liu, X.; Cao, W.; Zhang, L.; Zhang, S.; Yan, B.; Wang, Y.; Xia, C. Clusterin confers gemcitabine resistance in pancreatic cancer. World J. Surg. Oncol., 2011, 9, 59.
[http://dx.doi.org/10.1186/1477-7819-9-59] [PMID: 21609464]
[18]
Lee, C.H.; Jin, R.J.; Kwak, C.; Jeong, H.; Park, M.S.; Lee, N.K.; Lee, S.E. Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells. Urology, 2002, 60(3), 516-520.
[http://dx.doi.org/10.1016/S0090-4295(02)01806-X] [PMID: 12350509]
[19]
An, H.J.; Cho, N.H.; Yang, H.S.; Kwak, K.B.; Kim, N.K.; Oh, D.Y.; Lee, S.W.; Kim, H.O.; Koh, J.J. Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells. J. Pathol., 2007, 212(2), 161-169.
[http://dx.doi.org/10.1002/path.2158] [PMID: 17427168]
[20]
Zhang, C.; Nie, J.; Feng, L.; Luo, W.; Yao, J.; Wang, F.; Wang, H. The emerging roles of clusterin on reduction of both blood retina barrier breakdown and neural retina damage in diabetic retinopathy. Discov. Med., 2016, 21(116), 227-237.
[PMID: 27232509]
[21]
Koltai, T. Clusterin: A key player in cancer chemoresistance and its inhibition. OncoTargets Ther., 2014, 7, 447-456.
[http://dx.doi.org/10.2147/OTT.S58622] [PMID: 24672247]
[22]
Pucci, S.; Polidoro, C.; Joubert, A.; Mastrangeli, F.; Tolu, B.; Benassi, M.; Fiaschetti, V.; Greco, L.; Miceli, R.; Floris, R.; Novelli, G.; Orlandi, A.; Santoni, R. Ku70, Ku80, and sClusterin: A cluster of predicting factors for response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2017, 97(2), 381-388.
[PMID: 28068245]
[23]
Djeu, J.Y.; Wei, S. Clusterin and chemoresistance. Adv. Cancer Res., 2009, 105, 77-92.
[http://dx.doi.org/10.1016/S0065-230X(09)05005-2] [PMID: 19879424]
[24]
Niu, Z.H.; Wang, Y.; Chun, B.; Li, C.X.; Wu, L. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. Eur. Rev. Med. Pharmacol. Sci., 2013, 17(10), 1337-1344.
[PMID: 23740447]
[25]
Zhang, J.; Miao, C.; Xu, A.; Zhao, K.; Qin, Z.; Li, X.; Liang, C.; Hua, Y.; Chen, W.; Zhang, C.; Liu, Y.; Su, S.; Wang, Z.; Liu, B. Prognostic role of secretory clusterin in multiple human malignant neoplasms: A meta-analysis of 26 immunohistochemistry studies. PLoS One, 2016, 11(8)e0161150
[http://dx.doi.org/10.1371/journal.pone.0161150] [PMID: 27532124]
[26]
Zhang, D.; Sun, B.; Zhao, X.; Cui, Y.; Xu, S.; Dong, X.; Zhao, J.; Meng, J.; Jia, X.; Chi, J. Secreted CLU is associated with the initiation of triple-negative breast cancer. Cancer Biol. Ther., 2012, 13(5), 321-329.
[http://dx.doi.org/10.4161/cbt.19072] [PMID: 22310975]
[27]
Bi, J.; Guo, A.L.; Lai, Y.R.; Li, B.; Zhong, J.M.; Wu, H.Q.; Xie, Z.; He, Y.L.; Lv, Z.L.; Lau, S.H.; Wang, Q.; Huang, X.H.; Zhang, L.J.; Wen, J.M.; Guan, X.Y. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: A study on tissue microarrays. Neoplasma, 2010, 57(3), 191-197.
[http://dx.doi.org/10.4149/neo_2010_03_191] [PMID: 20353268]
[28]
Wei, L.; Xue, T.; Wang, J.; Chen, B.; Lei, Y.; Huang, Y.; Wang, H.; Xin, X. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int. J. Cancer, 2009, 125(4), 791-806.
[http://dx.doi.org/10.1002/ijc.24316] [PMID: 19391138]
[29]
Matsuwaki, R.; Ishii, G.; Zenke, Y.; Neri, S.; Aokage, K.; Hishida, T.; Yoshida, J.; Fujii, S.; Kondo, H.; Goya, T.; Nagai, K.; Ochiai, A. Immunophenotypic features of metastatic lymph node tumors to predict recurrence in N2 lung squamous cell carcinoma. Cancer Sci., 2014, 105(7), 905-911.
[http://dx.doi.org/10.1111/cas.12434] [PMID: 24814677]
[30]
Miyake, H.; Nelson, C.; Rennie, P.S.; Gleave, M.E. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res., 2000, 60(9), 2547-2554.
[PMID: 10811138]
[31]
So, A.; Sinnemann, S.; Huntsman, D.; Fazli, L.; Gleave, M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol. Cancer Ther., 2005, 4(12), 1837-1849.
[http://dx.doi.org/10.1158/1535-7163.MCT-05-0178] [PMID: 16373699]
[32]
July, L.V.; Beraldi, E.; So, A.; Fazli, L.; Evans, K.; English, J.C.; Gleave, M.E. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther., 2004, 3(3), 223-232.
[PMID: 15026542]
[33]
Chia, S.; Dent, S.; Ellard, S.; Ellis, P.M.; Vandenberg, T.; Gelmon, K.; Powers, J.; Walsh, W.; Seymour, L.; Eisenhauer, E.A. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin. Cancer Res., 2009, 15(2), 708-713.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1159] [PMID: 19147778]
[34]
Chi, K.N.; Hotte, S.J.; Yu, E.Y.; Tu, D.; Eigl, B.J.; Tannock, I.; Saad, F.; North, S.; Powers, J.; Gleave, M.E.; Eisenhauer, E.A. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2010, 28(27), 4247-4254.
[http://dx.doi.org/10.1200/JCO.2009.26.8771] [PMID: 20733135]
[35]
Beer, T.M.; Hotte, S.J.; Saad, F.; Alekseev, B.; Matveev, V.; Fléchon, A.; Gravis, G.; Joly, F.; Chi, K.N.; Malik, Z.; Blumenstein, B.; Stewart, P.S.; Jacobs, C.A.; Fizazi, K. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): A randomised, open-label, international, phase 3 trial. Lancet Oncol., 2017, 18(11), 1532-1542.
[http://dx.doi.org/10.1016/S1470-2045(17)30605-8] [PMID: 29033099]
[36]
Lamoureux, F.; Baud’huin, M.; Ory, B.; Guiho, R.; Zoubeidi, A.; Gleave, M.; Heymann, D.; Rédini, F. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget, 2014, 5(17), 7805-7819.
[http://dx.doi.org/10.18632/oncotarget.2308] [PMID: 25138053]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 2
Year: 2020
Published on: 12 February, 2020
Page: [131 - 139]
Pages: 9
DOI: 10.2174/1389201020666190821151120
Price: $65

Article Metrics

PDF: 26
HTML: 3